戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 acarbazine, IL-2 9 MU/m(2)/d for 4 days, and interferon alfa-2b).
2 he adverse effects were similar to those for interferon alfa-2b.
3 apy consisting of CVD plus interleukin-2 and interferon alfa-2b.
4 atment and after follow-up, as compared with interferon alfa-2b.
5 only complicates treatment with the cytokine interferon alfa-2b.
6 who are candidates for adjuvant therapy with interferon alfa-2b.
7 nfection were treated with standard doses of interferon alfa-2b.
8 nt with oral cimetidine (15% vs 5%), topical interferon alfa-2b (0% vs 1%), cryotherapy (0% vs 3%), p
9                       Treatment consisted of interferon alfa-2b 10 x 10(6) U subcutaneously three tim
10 odeficiency virus were randomized to receive interferon alfa-2b (3 million units 3 times a week) plus
11 two doses of CIFN (3 microg and 9 microg) or interferon alfa-2b (3 million units [MU]) weekly for 24
12 through 5 and as a bolus on days 12 and 19), interferon alfa-2b (3 million units subcutaneously three
13 ng either consensus interferon (9 microg) or interferon alfa-2b (3 million units) given three times w
14 ients treated with CIFN (9 microg) than with interferon alfa-2b (3 MU).
15 yotherapy with adjuvant topical or injection interferon alfa-2b (38% vs 15%).
16 sis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly syn
17 mes a week) plus ribavirin (1,000 mg/day) or interferon alfa-2b alone for 48 weeks with 24 weeks of p
18 oic acid may offer a superior alternative to interferon alfa-2b alone in treating CIN.
19 chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribaviri
20 ed in 3 published clinical trials evaluating interferon alfa-2b alone or with ribavirin either as ini
21 pared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of
22 umor-free period compared with studies using interferon alfa-2b alone.
23 s C (n = 103) were treated for 24 weeks with interferon alfa 2b and followed up for 24 weeks after ce
24 bazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2.
25 l of 1,744 patients with HCV received either interferon alfa-2b and placebo or combination interferon
26     We believe that combination treatment of interferon alfa-2b and retinoic acid may offer a superio
27 white nonresponders (NR) to a combination of interferon alfa-2b and ribavirin (IFN + R).
28 rly virologic response [EVR]) with pegylated interferon alfa-2b and ribavirin (PEG/R) in identifying
29 nterferon alfa-2b and placebo or combination interferon alfa-2b and ribavirin for 24 or 48 weeks.
30 alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatme
31 he efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chroni
32  For chronic hepatitis C, the combination of interferon alfa-2b and ribavirin is the treatment of cho
33                                Multiple-dose interferon alfa-2b and ribavirin peak and trough concent
34 ated the activity of combined treatment with interferon alfa-2b and sorafenib, a Raf and multiple rec
35 ll-known antiangiogenic agents (minocycline, interferon alfa-2b, and fumagillin) and were stored for
36 erapy, oral cimetidine, topical or injection interferon alfa-2b, and photodynamic therapy.
37 e, vinblastine, cisplatin, decrescendo IL-2, interferon alfa-2b, and tamoxifen was repeated at 21-day
38 evoflurane, the combination of ribavirin and interferon alfa-2b, and various betamethasone-containing
39 r alone or concurrent with interleukin-2 and interferon alfa-2b (BCT).
40 NA positive after 6 months of treatment with interferon alfa-2b but had a histological response.
41 (on days 5 to 8, 17 to 20, and 26 to 29) and interferon alfa-2b by subcutaneous injection (on days 5
42 atitis B, treatment with a 4-month course of interferon alfa-2b can achieve hepatitis B e antigen ser
43       Monotherapy with standard or pegylated interferon alfa-2b; combination therapy with standard or
44 ssigned to receive standard-dose recombinant interferon alfa-2b concurrently with ribavirin (1000 to
45 either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the once-weekly (QW)
46 in the mean serum HCV RNA concentration than interferon alfa-2b during treatment (P < .01).
47 mination prior to a single 6-month course of interferon alfa-2b; empirical interferon treatment; and
48 nts receiving a combination of ribavirin and interferon alfa-2b experienced an increased incidence of
49 day) or RBV (800-1400 mg/day) with pegylated interferon alfa-2b for 48 weeks.
50                            Patients received interferon alfa-2b for a minimum of 4 weeks, followed by
51 ompared peginterferon alfa-2b (PegIntron) to interferon alfa-2b for the initial treatment of compensa
52 he efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C.
53 e rates to 3, 5, or 10 million units (MU) of interferon alfa-2b, given thrice weekly, and to determin
54                               Treatment with interferon alfa-2b has been limited by its cost and low
55 therapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved
56                                    High-dose interferon alfa-2b (HDI) has emerged as a potentially ef
57                                    High-dose interferon alfa-2b (HDI) was administered concurrently,
58                           Adjuvant high-dose interferon-alfa-2b (HDI) improves disease-free and overa
59                        Adjuvant therapy with interferon alfa-2b holds promise for patients with metas
60                                              Interferon alfa-2b (IFN alpha-2b) exhibits antitumor act
61                  Although trials of adjuvant interferon alfa-2b (IFN alpha-2b) in high-risk melanoma
62 cted with HIV and HCV to receive 48 weeks of interferon alfa-2b (IFN) 3 million units three times wee
63 /m2, 5-FU 640 mg/m2/d as a 120-hour CIV, and interferon alfa-2b (IFN) at 2 MU/m2/d for 6 days for thr
64                                              Interferon alfa-2b (IFN) in a randomized clinical trial
65 for hepatitis C, we assessed the efficacy of interferon alfa-2b (IFN) in preventing recurrent hepatit
66 value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2
67          As second-line therapy, he received interferon alfa-2b (IFN--2b) 2.7 MU daily, which he tole
68 C melanoma were randomly assigned to receive interferon alfa-2b (IFN-alpha-2b) 20 MIU/m(2) intravenou
69 ession-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-alpha-2b) added to octreotide am
70                   Interleukin-12 (IL-12) and interferon alfa-2b (IFN-alpha-2b) are pleiotropic cytoki
71  tolerability of sorafenib administered with interferon alfa-2b (IFN-alpha-2b) as first- or second-li
72 estigated maintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients whose oste
73 d active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved u
74 pe 1 virus (HCV) is dependent on the dose of interferon alfa-2b (IFN-alpha2b), the acute clearance of
75 eron, with a standard regimen of recombinant interferon alfa-2b (IFN-alpha2b).
76 reliminary efficacy of once-weekly pegylated interferon alfa-2b (IFNalpha-2b) in patients with advanc
77                                    High-dose interferon alfa-2b (IFNalpha2b) is the only established
78    Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk mel
79                               In conclusion, interferon alfa-2b in combination with ribavirin is effe
80  all available randomized clinical trials of interferon alfa-2b in patients with chronic hepatitis C.
81 en subsequently used it, in combination with interferon alfa-2b, in a second cohort of this study and
82 polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chronic hepatitis C
83 ize that topical all-trans retinoic acid and interferon alfa-2b may act synergistically.
84 conditions were normalized by treatment with interferon alfa-2b or after expression of wild-type DOCK
85 radical nephrectomy followed by therapy with interferon alfa-2b or to receive interferon alfa-2b ther
86 er inflammation to a greater extent than did interferon alfa-2b, particularly in subjects with sustai
87                           Adjuvant pegylated interferon alfa-2b (PEG-IFN-alpha-2b) was approved for t
88 nts treated with variable-duration pegylated interferon alfa-2b (PEG-IFN-alpha2b) and RBV.
89 riple therapy with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which
90 on of therapy) than of patients who received interferon alfa-2b plus ribavirin (56 percent vs. 44 per
91                           Children receiving interferon alfa-2b plus ribavirin 15 mg/kg/d in the phas
92 a-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significa
93 stained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-
94                  Dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a
95 ety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alf
96 terferon alfa-2a than in the group receiving interferon alfa-2b plus ribavirin.
97 hout adjuvant oral cimetidine and/or topical interferon alfa-2b provide satisfactory tumor control.
98 I trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched wit
99                                  Recombinant interferon alfa-2b (rIFNalpha2b) is a standard therapy f
100 mized trial evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph nod
101            Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard a
102 herapy with interferon alfa-2b or to receive interferon alfa-2b therapy alone.
103             In comparison with no treatment, interferon alfa-2b therapy was associated with significa
104 apsed or were nonresponders to prior CIFN or interferon alfa-2b therapy.
105  toxicity associated with adjuvant high-dose interferon-alfa-2b therapy (HDI) for high-risk melanoma
106 herapy with at least 2 million units (MU) of interferon alfa-2b three times weekly for 24 weeks.
107 itis C virus (HCV) were treated with 5 MU of interferon alfa-2b three times weekly for 6 months.
108 were randomized to receive 3, 5, or 10 MU of interferon alfa-2b thrice weekly for 12 weeks.
109 2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin fo
110                                              Interferon alfa-2b-treated patients also had significant
111 rogressive pulmonary metastasis resistant to interferon alfa-2b treatment 7 months after he underwent
112 ery from melphalan, patients were to receive interferon alfa-2b until relapse.
113 in patients treated with CIFN (9 microg) and interferon alfa-2b was 7% and 0%, respectively (P = .03)
114 ation treatment of topical retinoic acid and interferon alfa-2b was effective in treating lesions wit
115                            Responses to 3 MU interferon alfa-2b were comparable to 9 microg CIFN.
116 y for 24 weeks, and lower doses of pegylated interferon alfa-2b were less effective than standard dos
117 1.0, 1.5 microg/kg) the clinical efficacy of interferon alfa-2b while preserving its safety profile.
118 azine, decrescendo interleukin-2 (IL-2), and interferon alfa-2b with granulocyte-macrophage colony-st

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top